Vanda Pharmaceuticals provides update on VQW-765 clinical development program
VNDA•Vanda Pharmaceuticals said its Phase III study of VQW-765 in social anxiety disorder did not meet its primary or key secondary endpoint in the full population. The drug was safe and well tolerated, and the program is on hold pending further analysis.
1. Phase III results
Vanda Pharmaceuticals said its Phase III study of VQW-765 in social anxiety disorder did not meet the primary endpoint or the key secondary endpoint in the full population. The company said VQW-765 was safe and well tolerated, and that the program is on hold pending further analysis.
